Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

2 papers

Anxiety

Based on 52 papers

Research points to two clear groups of treatments for anxiety. First, ordinary approaches like exercise — especially walking and other regular physical activity — have strong, high-quality evidence showing medium-sized reductions in anxiety symptoms. These are proven in many randomized trials and reviews. Second, newer substance-assisted therapies (often called psychedelic‑assisted therapy) are promising. Small clinical trials and reviews show reductions in anxiety and related problems after carefully supervised doses of drugs such as psilocybin, MDMA, ketamine, and ayahuasca. However, these drug approaches are mostly early-stage or done in special research settings and need more, larger trials before they can become routine care. People thinking about or treating anxiety should know that drug‑assisted therapies are almost always given together with serious psychological support. How the drug is given, the preparation before it, and follow-up therapy matter a lot. There are also safety and equity issues to watch: some psychedelics can have rare lasting side effects, many studies are small, and people of color have been underrepresented in trials. For now, exercise has the clearest and broadest evidence. Other treatments are promising but still need more testing and careful medical oversight.

Key findings

  • Many high-quality reviews find regular physical activity reduces anxiety by a medium amount across many trials. 8792
  • Walking specifically lowers anxiety symptoms compared with doing nothing, based on 26 randomized trials pooled together. 8785
  • Clinical trials and reviews report that psychedelic-assisted therapies (drugs given with therapy) reduced anxiety symptoms in people diagnosed with anxiety disorders. 15068 15063 15056
  • For post‑traumatic stress disorder (a trauma-related anxiety condition), MDMA given with psychotherapy produced large benefits in several controlled trials. 15063
  • Psychedelic drugs appear to change the brain in ways that could help anxiety and mood problems. Lab and imaging studies report increased brain plasticity (the brain’s ability to form new connections) and changes in inflammation and brain networks after substances like psilocybin, DMT, and other psychedelics. 15132 15050 15091 15135
  • Ketamine produces fast antidepressant effects and has been tested as an alternative to electroconvulsive therapy; it has also been studied for anxiety-related conditions in some trials. 10149 10160 15068
  • Most studies of psilocybin and other classic psychedelics are small and done with close medical and psychological support, so experts say larger, well‑controlled trials are still needed before routine use. 15056 15078
  • How people are prepared and supported matters a lot: many guides and reviews agree that screening, setting expectations, building trust, and follow‑up therapy are core parts of substance‑assisted psychotherapy. 15065 15092 15063
  • People of color were underrepresented in many psychedelic-assisted psychotherapy studies, which limits how well the results apply to different ethnic groups. 15095
  • There are risks to be aware of: rare but long-lasting perceptual problems (called HPPD) and other psychological or physical side effects have been reported after hallucinogen use, so safety monitoring is important. 15048 15087

Bedside to bench: the outlook for psychedelic research

Victor P. Acero, Emily S. Cribas, Kevin D. Browne, Olivia Rivellini, Justin C. Burrell, John C. O’Donnell, et al.
Frontiers in Pharmacology Summary & key facts 2023 18 citations

This paper is a review of recent research on psychedelic drugs. The authors say some clinical trials show these drugs can help people with post-traumatic stress disorder, substance abuse problems, and depression that has not improved with other treatments. But scientists do not yet understand all the biological ways these…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Nataliya S. Vorobyeva, Alena A. Kozlova
Frontiers in Pharmacology Summary & key facts 2022 14 citations

This paper reviews research on three naturally occurring psychedelics: psilocybin, ibogaine, and N,N-dimethyltryptamine (the active part of the brew ayahuasca). It explains that these drugs work on the brain's serotonin system and summarizes growing studies that suggest they might help with problems like post-traumatic stress disorder, major depression, anxiety, and…

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Ayahuasca Ibogaine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.